keyword
MENU ▼
Read by QxMD icon Read
search

Medicaid hepatitis c

keyword
https://www.readbyqxmd.com/read/29657956/results-of-a-hepatitis-c-virus-screening-program-of-the-1945-1965-birth-cohort-in-a-large-emergency-department-in-new-jersey
#1
Julia Kang Cornett, Vimal Bodiwala, Victor Razuk, Devangi Shukla, Navaneeth Narayanan
Background: Persons born between 1945 and 1965 account for an estimated 81% of those infected with hepatitis C virus (HCV) in the United States. However, up to 60% remain undiagnosed. Prior studies have reported HCV screening results from large urban emergency departments. Methods: This is a retrospective cohort study of patients in the 1945-1965 birth cohort tested for HCV in a large emergency department (ED) in New Jersey from June 1, 2016, through December 31, 2016...
April 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29578854/increasing-access-to-hepatitis-c-virus-medications-a-program-model-using-patient-navigators-and-specialty-pharmacy-to-obtain-prior-authorization-approval
#2
Trang M Vu, Wilma Toribio, Farah Riazi, Genesis Ciprian, Nathalia Gibbs, Martha Giardina, Jocelyn A Camacho, Korin Parrella, Joy Cambe, Catherine Amory, Rachel Chasan, Keith M Sigel, Jeffrey J Weiss
BACKGROUND: Obtaining prior authorization (PA) approval for the new direct-acting antiviral (DAA) hepatitis C medications is time consuming and requires specific expertise. Our primary care-based program treats hepatitis C virus (HCV)-infected patients at an urban academic medical center and employs patient navigators trained in the PA process who collaborate with a nurse and specialty pharmacy to manage the PA process. OBJECTIVE: To demonstrate the rate of PA approvals for our programmatic model and determine potential predictors of PA approval...
April 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29535247/moral-distress-with-obstacles-to-hepatitis-c-treatment-a-council-of-academic-family-medicine-educational-research-alliance-cera-study-of-family-medicine-program-directors
#3
Aditya Simha, Camille Maria Webb, Ramakrishna Prasad, N Randall Kolb, Peter J Veldkamp
BACKGROUND AND OBJECTIVE: To determine whether family medicine program directors (PDs) experienced moral distress due to obstacles to Hepatitis C virus (HCV) treatment, and to explore whether they found those obstacles to be unethical. DESIGN: An omnibus survey by the Council of Academic Family Medicine's Educational Research Alliance was administered to 452 and completed by 273 US-based PDs. The survey gauged attitudes and opinions regarding ethical dilemmas in patient access to HCV treatment...
March 2018: Journal of the American Board of Family Medicine: JABFM
https://www.readbyqxmd.com/read/29529669/risk-of-complications-after-tha-increases-among-patients-who-are-coinfected-with-hiv-and-hepatitis-c
#4
Siddharth A Mahure, Joseph A Bosco, James D Slover, Jonathan Vigdorchik, Richard Iorio, Ran Schwarzkopf
BACKGROUND: Individuals coinfected with both hepatitis C virus (HCV) and HIV represent a unique and growing population of patients undergoing orthopaedic surgical procedures. Data regarding complications for HCV monoinfection or HIV monoinfection are robust, but there are no data available, to our knowledge, on patients who have both HCV and HIV infections. QUESTIONS/PURPOSES: We sought to determine whether patients with coinfection differed in terms of baseline demographics and comorbidity burden as compared with patients without coinfection and whether these potential differences were translated into varying levels of postoperative complications, mortality, and hospital readmission risk...
February 2018: Clinical Orthopaedics and related Research
https://www.readbyqxmd.com/read/29523864/race-ethnicity-and-insurance-status-disparities-in-access-to-direct-acting-antivirals-for-hepatitis-c-virus-treatment
#5
Robert J Wong, Mamta K Jain, George Therapondos, Mitchell L Shiffman, Onkar Kshirsagar, Christopher Clark, Mae Thamer
OBJECTIVE: Despite availability of highly effective direct acting antivirals (DAA), barriers in access to these therapies limit our ability to achieve HCV eradication. We aim to evaluate overall rates and predictors of HCV treatment across four community-based health-care systems focusing on race/ethnicity and insurance-specific disparities. METHODS: We retrospectively evaluated all adults with chronic HCV at four health care systems from 1 January 2011 to 28 February 2017, which included a large proportion of ethnic minorities, two safety-net systems, and a broad payer mix across four states...
March 9, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29261241/insurance-switching-and-mismatch-between-the-costs-and-benefits-of-new-technologies
#6
David Cutler, Michael Ciarametaro, Genia Long, Noam Kirson, Robert Dubois
OBJECTIVES: Many therapies have immediate costs but delayed benefits. Recent and anticipated transformative therapies may exacerbate these challenges. This study explored whether disconnects between short-term budget impacts and long-term costs and benefits, and among impacts on initial payers, downstream payers, and society, are expected for a range of such therapies and whether they are likely consistent or variable, with implications for potential policy responses. STUDY DESIGN: Modeling...
December 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/29240798/the-cost-of-comorbidities-in-treatment-for-hiv-aids-in-california
#7
David S Zingmond, Kodi B Arfer, Jennifer L Gildner, Arleen A Leibowitz
BACKGROUND: Antiretroviral therapy has increased longevity for people living with HIV (PLWH). As a result, PLWH increasingly experience the common diseases of aging and the resources needed to manage these comorbidities are increasing. This paper characterizes the number and types of comorbidities diagnosed among PLWH covered by Medicare and examines how non-HIV comorbidities relate to outpatient, inpatient, and pharmaceutical expenditures. METHODS: The study examined Medicare expenditures for 9767 HIV-positive Californians enrolled in Medicare in 2010 (7208 persons dually covered by Medicare and Medicaid and 2559 with Medicare only)...
2017: PloS One
https://www.readbyqxmd.com/read/29211503/national-health-care-spending-in-2016-spending-and-enrollment-growth-slow-after-initial-coverage-expansions
#8
Micah Hartman, Anne B Martin, Nathan Espinosa, Aaron Catlin, The National Health Expenditure Accounts Team
Total nominal US health care spending increased 4.3 percent and reached $3.3 trillion in 2016. Per capita spending on health care increased by $354, reaching $10,348. The share of gross domestic product devoted to health care spending was 17.9 percent in 2016, up from 17.7 percent in 2015. Health spending growth decelerated in 2016 following faster growth in 2014 and 2015 associated with coverage expansions under the Affordable Care Act (ACA) and strong retail prescription drug spending growth. In 2016 the slowdown was broadly based, as spending for the largest categories by payer and by service decelerated...
January 2018: Health Affairs
https://www.readbyqxmd.com/read/29206910/state-medicaid-hepatitis-c-treatment-eligibility-criteria-and-use-of-direct-acting-antivirals
#9
Shashi N Kapadia, Philip J Jeng, Bruce R Schackman, Yuhua Bao
Medicaid program criteria for accessing hepatitis C treatment are changing. Using Medicaid drug utilization data from 2014-6, we found that programs that have relaxed their criteria have seen significant increases in treatment utilization compared to those that have not. States with Medicaid expansions also had marked increases in utilization.
December 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29151365/effectiveness-of-direct-acting-antiviral-therapy-for-hepatitis-c-in-difficult-to-treat-patients-in-a-safety-net-health-system-a-retrospective-cohort-study
#10
Christina Yek, Carolina de la Flor, John Marshall, Cindy Zoellner, Grace Thompson, Lisa Quirk, Christian Mayorga, Barbara J Turner, Amit G Singal, Mamta K Jain
BACKGROUND: Direct-acting antivirals (DAAs) have revolutionized chronic hepatitis C (HCV) treatment, but real-world effectiveness among vulnerable populations, including uninsured patients, is lacking. This study was conducted to characterize the effectiveness of DAAs in a socioeconomically disadvantaged and underinsured patient cohort. METHODS: This retrospective observational study included all patients undergoing HCV treatment with DAA-based therapy between April 2014 and June 2016 at a large urban safety-net health system (Parkland Health and Hospital System, Dallas, TX, USA)...
November 20, 2017: BMC Medicine
https://www.readbyqxmd.com/read/29147645/real-world-cure-rates-for-hepatitis-c-virus-treatments-that-include-simeprevir-and-or-sofosbuvir-are-comparable-to-clinical-trial-results
#11
Kian Bichoupan, Neeta Tandon, James F Crismale, Joshua Hartman, David Del Bello, Neal Patel, Sweta Chekuri, Alyson Harty, Michel Ng, Keith M Sigel, Meena B Bansal, Priya Grewal, Charissa Y Chang, Jennifer Leong, Gene Y Im, Lawrence U Liu, Joseph A Odin, Nancy Bach, Scott L Friedman, Thomas D Schiano, Ponni V Perumalswami, Douglas T Dieterich, Andrea D Branch
AIM: To assess the real-world effectiveness and cost of simeprevir (SMV), and/or sofosbuvir (SOF)-based therapy for chronic hepatitis C virus (HCV) infection. METHODS: The real-world performance of patients treated with SMV/SOF ± ribavirin (RBV), SOF/RBV, and SOF/RBV with pegylated-interferon (PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included...
November 12, 2017: World Journal of Virology
https://www.readbyqxmd.com/read/29072864/increased-risk-for-mother-to-infant-transmission-of-hepatitis-c-virus-among-medicaid-recipients-wisconsin-2011-2015
#12
Theresa Watts, Lauren Stockman, Justin Martin, Sheila Guilfoyle, James M Vergeront
State surveillance during the last 10 years reveals a nationwide increase in hepatitis C virus (HCV) infection among young adults (1). The proportion of infants born to HCV-infected women is also increasing nationally (2). To estimate the proportion of infants born to HCV-infected women and the frequency of confirmed HCV infection in their infants, maternal name and date of birth from HCV reports in the Wisconsin Electronic Disease Surveillance System (WEDSS) were linked to Wisconsin Medicaid data for 2011-2015 births...
October 27, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28957037/evaluation-of-the-impact-of-mandating-health-care-providers-to-offer-hepatitis-c-virus-screening-to-all-persons-born-during-1945-1965-new-york-2014
#13
Colleen A Flanigan, Shu-Yin J Leung, Kirsten A Rowe, Wendy K Levey, Andrea King, Jamie N Sommer, Johanne E Morne, Howard A Zucker
Approximately 75% of all hepatitis C virus (HCV) infections in the United States and 73% of HCV-associated mortality occur in persons born during 1945-1965, placing this birth cohort at increased risk for liver cancer and other HCV-related liver disease (1). In the United States, an estimated 2.7 million persons are living with HCV infection, and it is estimated that up to 75% of these persons do not know their status. Since 2012, CDC has recommended that persons born during 1945-1965 receive one-time HCV testing...
September 29, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28910222/restricted-access-state-medicaid-coverage-of-sofosbuvir-hepatitis-c-treatment
#14
Marea B Tumber
Chronic hepatitis C (HCV) infection can persist for decades without symptoms. Many Americans are unaware of their infection status and are not receiving necessary care and treatment. This places them at greater risk for severe, even fatal, complications from the disease and increases the likelihood that they will transmit the virus to others. In late 2013, the Food and Drug Administration approved a direct acting antiviral drug called sofosbuvir to treat chronic HCV infection. Sofosbuvir is a highly effective, but very expensive, curative treatment for HCV...
January 2017: Journal of Legal Medicine
https://www.readbyqxmd.com/read/28688150/national-assessment-of-early-hospitalization-after-liver-transplantation-risk-factors-and-association-with-patient-survival
#15
Pratima Sharma, Nathan P Goodrich, Douglas E Schaubel, Abigail R Smith, Robert M Merion
Hospitalization is known to occur frequently in the first 6 months following liver transplantation (LT). Using a novel data linkage between the Scientific Registry of Transplant Recipients and Centers for Medicare and Medicaid Services, our study has 2 objectives: (1) to determine risk factors for "early" hospitalization (ie, within 6 months of LT); and (2) to quantify the importance of hospitalization history in the first 6 months with respect to subsequent patient survival (ie, survival, conditional on surviving 6 months post-LT)...
September 2017: Liver Transplantation
https://www.readbyqxmd.com/read/28665676/the-oncogenic-hepatitis-c-virus-and-direct-acting-antivirals-economic-implications-for-hepatocellular-carcinoma-in-medicaid-beneficiaries-with-cirrhosis
#16
S Mantravadi
No abstract text is available yet for this article.
April 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28590325/uptake-of-and-factors-associated-with-direct-acting-antiviral-therapy-among-patients-in-the-chronic-hepatitis-cohort-study-2014-to-2015
#17
Philip R Spradling, Jian Xing, Loralee B Rupp, Anne C Moorman, Stuart C Gordon, Mei Lu, Eyasu H Teshale, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Scott D Holmberg
BACKGROUND: Limited information is available describing the uptake of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection among patients in general US health care settings. We determined the proportion of HCV-infected patients in the Chronic Hepatitis Cohort Study prescribed DAAs in 2014, who initiated treatment and identified characteristics associated with treatment initiation. METHODS: Uptake was defined as the proportion of HCV-infected patients with at least 1 clinical encounter in 2013 who were prescribed a DAA regimen during 2014 and initiated the regimen by August 2015...
June 5, 2017: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/28493854/state-hcv-incidence-and-policies-related-to-hcv-preventive-and-treatment-services-for-persons-who-inject-drugs-united-states-2015-2016
#18
Cecily A Campbell, Lauren Canary, Nicole Smith, Eyasu Teshale, A Blythe Ryerson, John W Ward
Hepatitis C is associated with more deaths in the United States than 60 other infectious diseases reported to CDC combined. Despite curative hepatitis C virus (HCV) therapies and known preventive measures to interrupt transmission, new HCV infections have increased in recent years (1,2). Injection drug use is the primary risk factor for new HCV infections (2). One potential strategy to decrease the prevalence of HCV is to create and strengthen public health laws and policies aimed specifically at reducing transmission risks among persons who inject drugs...
May 12, 2017: MMWR. Morbidity and Mortality Weekly Report
https://www.readbyqxmd.com/read/28465360/male-sex-associated-with-increased-risk-of-neonatal-abstinence-syndrome
#19
M Katherine Charles, William O Cooper, Lauren M Jansson, Judith Dudley, James C Slaughter, Stephen W Patrick
BACKGROUND: Neonatal abstinence syndrome (NAS) is a postnatal opioid withdrawal syndrome. Factors associated with development of the syndrome are poorly understood; however, infant sex may influence the risk of NAS. Our objective was to determine if infant sex was associated with the development or severity of the syndrome in a large population-based cohort. METHODS: This retrospective cohort study used vital statistics and prescription, outpatient, and inpatient administrative data for mothers and infants enrolled in the Tennessee Medicaid program between 2009 and 2011...
June 2017: Hospital Pediatrics
https://www.readbyqxmd.com/read/28426313/restrictions-of-hepatitis-c-treatment-for-substance-using-medicaid-patients-cost-versus-ethics
#20
Joshua M Liao, Michael A Fischer
Medicaid programs provide health insurance coverage for many patients with hepatitis C, a public health problem for which effective but very expensive treatments are now available. Facing constrained budgets, most states adopted prior authorization criteria for sofosbuvir, the first of these agents. Using fee-for-service utilization data from 42 Medicaid programs in 2014, we found that strict behavioral criteria-those that limited coverage on the basis of drug or alcohol use and included specific abstinence or treatment requirements-were associated with significantly less spending on sofosbuvir...
June 2017: American Journal of Public Health
keyword
keyword
90227
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"